CCL18 and interstitial lung disease: CCL18 (126), MMP7 (157), SP-D (74, 158), and interleukin-6 (IL-6) (136) have each demonstrated potential in predicting near-term FVC decline in patients with ILD, though none with sufficient risk explanation to justify clinical implementation to date.